lopinavir ritonavir  (AbbVie Inc)

Journal: Acta Pharmaceutica Sinica. B

Article Title: Solubilization techniques used for poorly water-soluble drugs

doi: 10.1016/j.apsb.2024.08.027

Figure Lengend Snippet: SEDDSs products in the clinic.

Article Snippet: Kaletra , Ritonavir Lopinavir , HIV infection , Polyoxyl 40 hydrogenated castor oil , AbbVie , 2000 , .

Techniques: Transplantation Assay, Infection

Journal: Viruses

Article Title: 3-Chymotrypsin-like Protease (3CLpro) of SARS-CoV-2: Validation as a Molecular Target, Proposal of a Novel Catalytic Mechanism, and Inhibitors in Preclinical and Clinical Trials

doi: 10.3390/v16060844

Figure Lengend Snippet: 3CLpro inhibitors of SARS-CoV-2. Column headings include the molecule name, structure, IC 50 , K i , CC 50 , EC 50 , and reference, representing the structural name, structural representation, half-maximal inhibitory concentration, inhibition constant, half-maximal cytotoxic concentration, half-maximal effective concentration against SARS-CoV-2 (that were propagated and tittered in Vero-E6 cells), and the respective reference for the provided data. The physical chemistry parameters MW, TPSA, HDA, HBD, and consensus Log P were estimated from the SwissADME website [ 85 , 86 ].

Article Snippet: Lopinavir and Ritonavir , Abbvie , Oral , Discontinued , 13,700.0 # , 26.6 * , NCT04381936.

Techniques: Concentration Assay, Inhibition

Journal: Viruses

Article Title: 3-Chymotrypsin-like Protease (3CLpro) of SARS-CoV-2: Validation as a Molecular Target, Proposal of a Novel Catalytic Mechanism, and Inhibitors in Preclinical and Clinical Trials

doi: 10.3390/v16060844

Figure Lengend Snippet: 3CLpro inhibitors in preclinical and clinical trials. The table provides an overview of 3CLpro inhibitors in preclinical and clinical trials. Each row represents a specific molecule under investigation, with information about the 3CLpro inhibitors’ name, the pharmaceutical company responsible for their development, the route of administration, the current state of development, the inhibitory concentration (IC 50 ) in nanomolar for 3CLpro inhibitors in preclinical trials, the effective concentration (EC 50 ) in micromolar for 3CLpro inhibitors in preclinical or clinical trials, and the unique identifier (ID) of the registered clinical trial. These data offer a comprehensive perspective on 3CLpro inhibitors in the research and development phase for potential use in treating COVID-19.

Article Snippet: Lopinavir and Ritonavir , Abbvie , Oral , Discontinued , 13,700.0 # , 26.6 * , NCT04381936.

Techniques: Concentration Assay